National Academies Press: OpenBook

Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary (2005)

Chapter: Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema

« Previous: Appendix E Description of the Laudabaum Colorectal Cancer Screening Model--Uri Ladabaum, M.D., M.S.
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

Appendix F
MISCAN-colon: An Overview Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmarssen, and Dik Habbema

SLIDE 1

SLIDE 1 NOTES: No notes.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 2

SLIDE 2 NOTES: Elements of the Miscan Model’s structure are shown in this frame. The micro-simulation model treats time as a continuous variable, with discrete events occurring along the time line. So, for example, the appearance of a polyp of a particular size is a discrete event. (The model identifies three sizes.) But the dwelling time of such a polyp before it progresses to a larger size can be any length. Probability functions determine when the transition from one state to another will occur.

By parallel universe, we mean that the model first generates a complete simulated, or hypothetical, population of individuals with their complete natural history in the absence of screening. The results of that baseline simulation, with all pertinent clinical details, are stored. Then, the model begins again with the same population as before, but this time a particular screening strategy is imposed. Assumptions about the effect of screening on the clinical course of each patient determine a new set of simulated results. The net effect of the screening strategy is determined per life history by the changes that occur compared with the baseline.

The model provides outputs on a real population in any specific calendar year. Most of our published work has taken that approach. However, the model is flexible in that a specific cohort of individuals (such as 50 year old men) can be followed throughout the rest of their lives. For the pre-workshop exercise, we did adapt the model to a cohort structure.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 3

SLIDE 3 NOTES: The model is also a multi-disease model. By that I mean two things. First, although the model is intended to simulate a general population, it recognizes the inherent variation among individuals in the risk of developing adenomas and cancer. Thus, each individual has his own probability of acquiring one more adenomas.

Second, adenomas are simulated as distinct occurrences in the same person. One or more can occur simultaneously or over time. For example, a person’s simulated natural history might be programmed to develop a non-progressive adenoma in the rectum at one time, and another progressive adenoma in the transverse colon at another time. Each of these events will have their own independent history until a first cancer is detected in that simulated individual.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 4

SLIDE NOTES 4: This chart shows the disease states and transitions that are included in the model. For example, a person with no adenomatous lesions may develop a small adenoma, which may or may not progress into cancer.

The length of time required for each person to travel through each phase in the adenoma/carcinoma sequence is determined by the parameters of a probability distribution for each disease stage and for each transition that is specified as part of the model.

The model as currently quantified does not permit a cancer to derive directly from a small adenoma. The adenoma must first progress to a medium or large size. Once the transition to cancer occurs, the lesion progresses through four stages. In any stage there is a chance, based on an assumed probability of detection, that the lesion will be diagnosed and become a clinical case. Once clinical, the lesion will or will not cause the patient’s death from colorectal cancer with a specific probability specific to each stage.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 5

SLIDE 5 NOTES: The parameters used to generate each hypothetical person’s history were derived from a variety of sources, including data produced in clinical and epidemiological studies and, when no reliable data were available, expert opinion.

We started with data on the US population by age and calendar year. We also used SEER CRC incidence data from the late 1970’s before screening was prevalent in the USA. We also used the extant autopsy studies to estimate adenoma prevalence, including the prevalence of multiple adenomas in the same individual.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 6

SLIDE 6 NOTES: This chart provides an overview of which parameters were based on direct estimates and which resulted from a statistical fit procedure. Those based on assumptions are the ones that we must investigate when we validate the model, because they are the ones for which there are inadequate data from screening studies at present. They include the duration and distribution of the preclinical state and, closely connected, the transition probabilities from one preclinical state to another.

We assumed that it takes, on average, 20 years from the start of a small adenoma to a clinical cancer. We have attempted to validate this assumption with adenoma endoscopy studies, but more such studies are needed for us to be fully confident in that assumption. Another assumption regards the correlation among durations in different preclinical disease states. For now, we assume that if an individual progresses rapidly through the small adenoma state, he or she has a high probability of progressing rapidly through later states. We also assume a positive correlation among the durations of preclinical cancerous states.

At present, the results of screening tests are assumed to be independent of earlier or later tests, but we do not have data to support or reject this assumption. We also assumed that the same stage-specific survival holds for cancers detected through a screening procedure as for those detected through presentation of clinical symptoms. Thus, all the gain from early detection of cancer through screening results from a shift in the stages at which cancers are detected. Better data are needed to determine whether this assumption is justified.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 7

SLIDE 7 NOTES: To arrive at realistic assumptions about the degree of compliance that can be expected from a particular screening strategy, we relied on data reported from clinical trials and population surveys. Population surveys are problematic as a source of compliance estimates, because the population has a choice of 3 or more different screening technologies for colorectal cancer screening, and the surveys do not ALWAYS provide detailed information on the specific test received. Applying compliance rates found in surveys to a screening strategy involving only one procedure (e.g., sigmoidoscopy every 5 years) could result in errors.

Our model assumes that the probability of compliance with the screening strategy at any screening round depends on the person’s compliance history in the previous screening round. Compliance in one round implies, in the model, a higher probability of compliance in the successive round. The probability of attending screening when attended previously is four times the probability when not attended the previous round. The total percentage of people who are attenders is constant over time.

Compliance with all diagnostic follow-up and post-adenoma detection surveillance is assumed to be 100 percent.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 8

SLIDE 8 NOTES: Our assumptions about the costs of screening, follow-up and surveillance procedures are shown elsewhere in the workshop summary. The costs of CRC treatment vary with the number of months since the detection of a CRC. Initial treatment costs cover the first six months; after that, continued CRC-related costs are charged over the remainder of the life, until the last six months, when costs of terminal care are included.

However, for the pre-workshop exercise, because individuals would be followed only until age 85, we did not include terminal care costs, even when a simulated person died before the age of 85.

We include only those costs associated with treating CRC. Unrelated medical care costs are not included, nor are any non-medical costs, such as transportation or work losses.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 9

SLIDE 9 NOTES: We have attempted to validate the model’s predictions by comparing them with the results of several screening and surveillance trials. In comparison to the National Polyp Study (a trial of post-polypectomy surveillance) Miscan predicted more cancers in the years following polypectomy than was reported in the trial (Loeve et al., 2004). In comparison to the Kaiser Flexible sigmoidoscopy study (Levin and Palitz, 2002) we also found too many cancers during the 5 years following a negative sigmoidoscopy (van Ballegooijen et al., 2002). So, we predicted too many cancers during follow up in individuals both with and without adenomas, while our total risk for cancer was calibrated to the total population. To explain the sigmoidoscopy data, we need to adjust our model so that risk is shifted away from individuals with few or now adenomas. Consequently, individuals with adenomas (as in the National Polyp Study) on average will have an increased risk. But this is not compatible with the National Polyp Study, where we already simulated too many cancers. On the other hand, since neither of these two studies was randomized before entry, it cannot be ruled out that the study groups consist of relatively low-risk individuals through self-selection (in the sigmoidoscopy study) or through clinical selection (in the NPS). This shows why we badly need randomized studies for further validation.

We have been able to reproduce the results of the Minnesota trial. Our model predicted a 34.6 percent reduction in morality from annual screening and a 20 percent reduction from biennial screening. In the Minnesota trial the observed reductions were 33 percent and 21 percent, respectively. Although we reproduce the mortality reduction found in that trial, the model did not predict the stage distribution in follow-up rounds so

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

well. The model predicted a much more favorable stage distribution than was found in the Minnesota trial. That failure may suggest problems if we are to use the model for improved tests or other strategies. We are therefore currently attempting to validate the model against the three big FOBT trials together, combining the data that are available from each one.

SLIDE 10

SLIDE 10 NOTES: No notes.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×

SLIDE 11

SLIDE 11 NOTES: No notes.

REFERENCES

Levin TR, Palitz AM. 2002. Flexible sigmoidoscopy: An important screening option for average-risk individuals. Gastrointest Endosc Clin N Am. 12(1):23–40.

Loeve F, Boer R, Zauber AG, Van Ballegooijen M, Van Oortmarssen GJ, Winawer SJ, Habbema JDF. 2004. National Polyp Study data: Evidence for regression of adenomas. Int J Cancer. 111(4):633–639.


van Ballegooijen M, et al. 2002. Validation Study of the Miscan-Colon Program Sith Data From the CoCaP Sigmoidoscopy Program. Final Report to NCI. Rotterdam, NE: Erasmus Medical Center.

Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 73
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 74
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 75
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 76
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 77
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 78
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 79
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 80
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 81
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 82
Suggested Citation:"Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Institute of Medicine and National Research Council. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11228.
×
Page 83
Next: Appendix G The Vanderbilt Colorectal Cancer Model--R.M. Ness, R.W. Klein, R.S. Dittus »
Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary Get This Book
×
Buy Paperback | $75.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The National Cancer Policy Board and the Board on Science, Engineering, and Economic Policy convened a workshop in January 2004 on “Economic Models of Colorectal Cancer (CRC) Screening in Average-Risk Adults”. The purpose of the workshop was to explore the reasons for differences among leading cost-effectiveness analysis (CEA) models of CRC screening, which public health policy makers increasingly rely on to help them sift through the many choices confronting them. Participants discussed the results of a collaborative pre-workshop exercise undertaken by five research teams that have developed and maintained comprehensive models of CRC screening in average-risk adults, to gain insight into each model’s structure and assumptions and possible explanations for differences in their published analyses. Workshop participants also examined the current state of knowledge on key inputs to the models with a view toward identifying areas where further research may be warranted. This document summarized the presentations and discussion at the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!